MedTrace Logo

Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion

NCT01710839 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-09-08

Study results available
· View outcomes & findings →

Summary

To see if Lucentis 0.5mg combined with Targeted Pan Retinal photocoagulation will decrease the total number of intravitreal injections in a year for ischemic central retinal vein occlusion, hemi-retinal vein occlusions and branch retinal vein occlusions compared to standard of care

Conditions

  • Central Retinal, Hemi Retinal & Brach Retinal Vein Occlusions

Interventions

DRUG

0.5mg Ranibizumab

intravitreal injections

PROCEDURE

Targeted Pan Retinal Photocoagulation

Targeted Pan Retinal Photocoagulation based on wide field angiography

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Charles C Wykoff, PhD, MD

    lead OTHER

Principal Investigators

  • Charles C Wykoff, PhD, MD · Retina Consultants Houston

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2015-10-31
Completion
2015-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01710839 on ClinicalTrials.gov